240 related articles for article (PubMed ID: 11157603)
21. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
[TBL] [Abstract][Full Text] [Related]
22. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
[TBL] [Abstract][Full Text] [Related]
24. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Xu S; Xiong S; Xu Y; Liu J; Liu H; Zhao J; Xiong W
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):421-4. PubMed ID: 17120738
[TBL] [Abstract][Full Text] [Related]
26. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
27. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
Höffken G; Barth J; Rubinstein E; Beckmann H;
Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
[TBL] [Abstract][Full Text] [Related]
28. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
30. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
[TBL] [Abstract][Full Text] [Related]
33. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
34. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
36. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
37. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial.
Llor C; Pérez A; Carandell E; García-Sangenís A; Rezola J; Llorente M; Gestoso S; Bobé F; Román-Rodríguez M; Cots JM; Hernández S; Cortés J; Miravitlles M; Morros R
Aten Primaria; 2019 Jan; 51(1):32-39. PubMed ID: 29061311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
